ACOG Updates Menopause Guidance, Expanding Treatment Options for Common Symptoms
By Emma Carter
Image information
This is a representative image for this Daily News lesson.
Intro
The American College of Obstetricians and Gynecologists has revised its recommendations for treating menopause-related symptoms, widening the range of therapies clinicians may consider for individual patients.
Vocabulary
| Word | Part of speech | Meaning | Example |
|---|---|---|---|
| individualized adjective | adjective | Meaning: tailored to the characteristics, needs, or circumstances of a particular person | Example: The clinic provides individualized advice after reviewing each patient's medical history. |
| reassessment noun | noun | Meaning: a renewed evaluation of something in light of additional evidence or changed circumstances | Example: A reassessment of the data revealed that the initial conclusion was overly broad. |
| limitations noun | noun | Meaning: shortcomings or restrictions that reduce the scope, reliability, or applicability of something | Example: The researchers acknowledged several limitations in the study's sampling method. |
| symptomatic adjective | adjective | Meaning: experiencing noticeable symptoms associated with a medical condition | Example: Treatment is generally considered only when patients are sufficiently symptomatic. |
| systemic adjective | adjective | Meaning: affecting the body as a whole rather than a single localized area | Example: The physician explained how systemic medication differs from a topical preparation. |
| progestogen noun | noun | Meaning: a natural or synthetic hormone that has effects similar to progesterone | Example: The specialist prescribed a progestogen to protect the uterine lining. |
| endometrial adjective | adjective | Meaning: relating to the inner lining of the uterus | Example: The scan showed no evidence of endometrial abnormalities. |
| perimenopause noun | noun | Meaning: the transitional period preceding menopause, during which reproductive and hormonal changes occur | Example: Some people experience substantial sleep disruption during perimenopause. |
The story
The American College of Obstetricians and Gynecologists has updated its recommendations for treating symptoms associated with menopause, issuing its first revision since 2014. The guidance, released Thursday, focuses on matching treatment to particular symptoms rather than presenting menopause care as a single, uniform decision.
ACOG recommends considering hormone replacement therapy alongside certain antidepressants, nonhormonal medicines, and other approaches for symptoms such as hot flashes, insomnia, and mood changes. Catherine Cansino, chair of ACOG’s Committee on Clinical Practice Guidelines and a co-author of the recommendations, said the expanded range of treatments allows clinicians to take a more individualized approach.
The guidance also reflects a reassessment of earlier concerns about hormone therapy. In 2002, findings from the Women’s Health Initiative suggested that hormone replacement therapy could raise the risks of heart disease, breast cancer, stroke, and pulmonary embolism. Researchers later identified limitations in that evidence, including the fact that most participants were at least 60 years old. That made the results harder to apply to younger people entering menopause or experiencing perimenopause.
According to the updated recommendations, hormone therapy is likely to be the most effective option for symptomatic people who have recently entered menopause, particularly those within 10 years of their final menstrual period or younger than 60. However, it is not suitable for everyone. The guidance lists undiagnosed abnormal genital bleeding, certain gynecologic cancers, blood clots, stroke, heart attack, liver disease, and known or suspected pregnancy among reasons to avoid it.
For people with a uterus, systemic hormone therapy generally combines estrogen with progestogen. Estrogen can stimulate the uterine lining, while progestogen helps reduce the resulting risk of endometrial cancer.
ACOG also highlights newer nonhormonal options. Fezolinetant, sold as Veozah, was approved by the Food and Drug Administration for hot flashes in 2023, while elinzanetant, sold as Lynkuet, received approval in 2025. These medicines work by blocking chemical messengers involved in regulating body temperature and sleep-wake cycles.
The recommendations note that about two million women begin menopause each year, while symptoms may start years before the final menstrual period. The average age at menopause is 49.9 years.
Warm-up questions
- How should medical guidance balance standardized evidence with an individual patient's circumstances?
- What factors might make a treatment recommendation unsuitable for a particular patient?
Comprehension questions
- What central change does the updated guidance make to the way menopause care is framed?
- Why did researchers later question how broadly the 2002 hormone-therapy findings could be applied?
- For which group does the guidance identify hormone therapy as especially effective?
- What protective role does progestogen play in systemic therapy for people with a uterus?
- What do Fezolinetant and elinzanetant have in common according to the article?
Opinion questions
- Does individualized treatment necessarily produce better care than a more standardized protocol? Explain your position.
- Should medical organizations foreground treatment risks even when later evidence qualifies earlier concerns?
Further discussion
- How might age, timing, symptom profile, and contraindications interact when clinicians recommend therapy?
- What challenges could arise when new medicines expand the range of clinically available options?
Writing prompt
- Write a critical briefing explaining how the updated guidance balances broader treatment options with evidence-based exclusions and individualized decision-making.
